OPPM
CTMX icon

Opus Point Partners Management’s CytomX Therapeutics CTMX Stock Holding History

Opus Point Partners Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,284
Closed -$272K – 67
2019
Q1 		$272K Buy
+25,284
New +$374K 0.37% 63

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Opus Point Partners Management's CTMX Position: Q2 2019 in Review

Opus Point Partners Management sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 25,284 shares — an estimated $272K sold.

Opus Point Partners Management first reported a position in CTMX in Q1 2019 and held it in 1 quarter. The position peaked at $272K in Q1 2019. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Opus Point Partners Management reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 25,284 CytomX Therapeutics shares in Q2 2019, an estimated $272K.
  • Opus Point Partners Management first reported a position in CytomX Therapeutics in Q1 2019 and held it in 1 quarter.
  • Opus Point Partners Management's CytomX Therapeutics position peaked at $272K in Q1 2019.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.